New developments in cognitive behavioral therapy as the first-line treatment of insomnia by Siebern, Allison T & Manber, Rachel
© 2011 Siebern and Manber, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Psychology Research and Behavior Management 2011:4 21–28
Psychology Research and Behavior Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
21
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/PRBM.S10041
New developments in cognitive behavioral 
therapy as the first-line treatment of insomnia
Allison T Siebern
Rachel Manber
Sleep Medicine Center, Stanford 
University School of Medicine, 
Redwood City, California, USA
Correspondence: Allison T Siebern 
Sleep Medicine Center, Stanford 
University, School of Medicine,  
450 Broadway St, M/C 5704,  
Redwood City, CA 94063, USA 
Tel +1 (650) 721 7558 
Fax +1 (650) 721 3468 
email asiebern@stanford.edu
Abstract: Insomnia is the most common sleep disorder. Psychological, behavioral, and 
biological factors are implicated in the development and maintenance of insomnia as a disorder, 
although the etiology of insomnia remains under investigation, as it is still not fully understood. 
Cognitive behavioral therapy for insomnia (CBTI) is a treatment for insomnia that is grounded 
in the science of behavior change, psychological theories, and the science of sleep. There is 
strong empirical evidence that CBTI is effective. Recognition of CBTI as the first-line treatment 
for chronic insomnia (National Institutes of Health consensus, British Medical Association) 
was based largely on evidence of its efficacy in primary insomnia. The aim of this article is to 
provide background information and review recent developments in CBTI, focusing on three 
domains: promising data on the use of CBTI when insomnia is experienced in the presence of 
comorbid conditions, new data on the use of CBTI as maintenance therapy, and emerging data 
on the delivery of CBTI through the use of technology and in primary care settings.
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Introduction
Insomnia is the most common sleep disorder. It may present as the primary issue or in 
parallel with a coexisting medical or psychiatric condition. Psychological, behavioral, 
and biological factors are implicated in the development and maintenance of insomnia 
as a disorder, although the etiology of insomnia remains under investigation, as it is 
still not fully understood. Two types of treatment for insomnia disorder have received 
adequate empirical support: hypnotic medications and cognitive behavioral therapy 
for insomnia (CBTI). The aim of this article is to provide background information 
and review recent developments in CBTI, focusing on three domains: promising data 
on the use of CBTI when insomnia is experienced in the presence of comorbid condi-
tions, new data on the use of CBTI as maintenance therapy, and emerging data on the 
delivery of CBTI through the use of technology and in primary care settings.
Overview of insomnia
insomnia as a diagnosis
Estimates of the prevalence of insomnia disorder in the US range between 6% and 10%.1,2 
Insomnia disorder is characterized by night-time symptoms (difficulties initiating 
and/or maintaining sleep, or nonrestorative sleep) and daytime symptoms (distress 
and/or impairment in daytime functioning, such as difficulty with concentration, 
memory, fatigue, and/or mood). The diagnostic criteria also require that symptoms are 
present for at least 1 month.3,4 The word “insomnia” has been used interchangeably Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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in the literature to refer to insomnia symptoms and insomnia 
disorder. To eliminate this ambiguity, sleep researchers have 
reserved the term “insomnia symptoms” to distinguish it from 
insomnia as a sleep disorder.5 We have adapted this distinction 
in the present manuscript. Insomnia can be classified by its 
duration: transient (less than a month), short term (between 
1 month and 6 months), and chronic (more than 6 months).
Sleep specialists use the International Classification of 
Sleep Disorders (ICSD-II) as nosology. It includes general 
insomnia criteria and lists 10 types of insomnia: adjustment 
insomnia, psychophysiologic insomnia, paradoxical insomnia, 
idiopathic insomnia, inadequate sleep hygiene, insomnia 
due to mental disorder, insomnia due to drug or substance, 
insomnia due to medical condition, insomnia unspecified, 
and physiological insomnia.3 Mental health practitioners 
typically use the Diagnostic and Statistical Manual of Mental 
Disorders, which, at present (4th edition), includes criteria 
for primary insomnia or insomnia related/due to a substance 
or another medication, a psychiatric or medical condition, or 
another sleep disorder.4 The DSM V advisory committee on 
sleep nosology has proposed a single diagnosis of “insomnia 
disorder” that includes what was previously primary insomnia 
and insomnia related to medical or psychiatric conditions, 
and proposed the use of qualifiers to specify the presence of 
medical and/or psychiatric comorbidities.6
insomnia development and maintenance
As previously stated, the etiology of insomnia remains 
under investigation, as it is still not well understood. There 
are various models of insomnia, none of which completely 
explains the etiology of insomnia disorder, as it is a complex 
and most likely multifactorial phenomenon. Insomnia can 
involve some level of physiological hyperarousal that can 
interfere with sleep initiation and/or maintenance. Studies 
have demonstrated a relationship between those with primary 
insomnia and those with physiologic factors such as increased 
whole-body metabolic activation, abnormal hormone secre-
tion, variable heart rate, increased high-frequency electroen-
cephalography activation, and sympathetic nervous system 
activation during sleep.7–11 It remains unclear whether physi-
ological hyperarousal predisposes people to the development 
of insomnia disorder or whether physiological hyperarousal 
is a result of the disorder.
A cognitive model of the maintenance of insomnia 
was proposed by Harvey.12 In this model, it is suggested 
that the initial development of acute insomnia can be due 
to a life stressor. When worry about the insomnia and 
daytime consequences related to not obtaining enough 
sleep becomes present, this anxiety can trigger emotional 
distress and autonomic activation. As the anxiety related to 
sleep continues, selective attention to sleep-related threats, 
both internal (feelings of bodily sensations such as fatigue 
during the day, alertness when attempting to fall asleep) 
and external (watching the clock and calculating how much 
time is left to sleep, how long they were actually asleep), 
and inaccurate perceptions of daytime impairment (such as 
perceived work or school performance deficits) can occur. 
“Safety behaviors” can get put into place, such as canceling 
or avoiding daytime activities/obligations due to the sleep 
issue or drinking alcohol before bedtime to assist with sleep 
onset. This can lead to physiologic arousal, which may per-
petuate the insomnia.12
Another model of the development and maintenance of 
insomnia was put forth by Spielman et al13 in 1987. They 
proposed a behavioral model of insomnia that identifies three 
factors: predisposing factors, precipitating events, and perpet-
uating attitudes and practices. Predisposing factors lower the 
threshold for the potential development of insomnia disorder 
and can include biological and psychological characteristics. 
Predispositions increase the risk for developing insomnia 
when precipitating events emerge. An example of a predis-
position is a tendency for excessive worry, which is likely to 
increase basal sympathetic activation. A precipitating event 
is usually associated with distress. Examples of precipitating 
events include concern about job loss, illness, and death of a 
loved one. Around 75% of people with insomnia can identify 
what triggered the episode.14 A person’s response to the expe-
rience of poor sleep may perpetuate the problem. Responding 
to sleep disruptions with distress about sleep often leads to 
increased efforts to sleep and engagement in behaviors that, 
although they aim to facilitate sleep, lead to worsening of 
the sleep problem. For example, trying to improve sleep by 
staying in bed longer than before the insomnia developed 
rarely increases the actual amount of sleep obtained. Instead, 
it increases the time spent frustrated and tossing and turning 
and renders the bed a cue for sleeplessness, thus worsening 
and potentially prolonging the problem. If a person responds 
to poor sleep with distress, this can also lead to adopting 
maladaptive and inaccurate beliefs and cognitions that create 
increased anxiety, such as “performance anxiety”, anxiety 
about being able to sleep. Increases in anxiety in turn make 
it harder to sleep.
CBTI targets these and other compensatory behaviors 
and maladaptive cognitions. It includes behavioral compo-
nents, specifically stimulus control instructions and sleep 
restriction therapy, cognitive therapy, relaxation and other Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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stress reduction techniques, and sleep hygiene education 
(see Table 1).15–21 CBTI is anchored in the science of behavior 
change, psychological theories, and the science of sleep.
CBTI as first-line treatment  
of insomnia
There is strong empirical evidence that CBTI is effective.22 
CBTI demonstrates comparable efficacy with more durable 
long-term maintenance of gains after treatment discontinu-
ation in randomized controlled trials of direct comparisons 
of CBTI with sleep medication.23–25 It has been proposed that 
skills are learned in CBTI that the patient can implement 
on their own long term beyond discontinuation of CBTI 
treatment, whereas medication use needs to continue in order 
to retain the benefit.
Meta-analyses have found robust effect sizes for the 
treatment components of CBTI.22,26–28 A meta-analysis 
of 23 randomized controlled trials, comparing studies that 
enrolled participants aged 55 years and older with studies 
that enrolled those, on average, younger than 55 years, 
found significant effects of behavioral interventions for sleep 
latency (adults Cohen’s d = -0.52, older adults Cohen’s 
d = -0.51), sleep quality (adults Cohen’s d = 0.89, older 
adults Cohen’s d = 0.60), wakefulness after sleep onset 
(adults Cohen’s d = -0.57, older adults Cohen’s d = -0.73), 
and sleep efficiency (adults Cohen’s d = 1.00, older adults 
Cohen’s d = 0.38) in both groups and for total sleep time 
in the younger cohort (adults Cohen’s d = 0.42, older 
adults Cohen’s d = -0.19). The behavioral interventions 
appeared more effective in the younger cohort for sleep 
efficiency.26 A meta-analysis of the short-term efficacy 
of pharmacotherapy (benzodiazepines or benzodiazepine 
receptor agonists) was compared with behavioral therapy 
(stimulus control and sleep restriction) for primary insomnia 
in 21 studies using prospective measures and within-subject 
designs. Comparable short-term outcomes were seen for both 
pharmacotherapy and behavioral therapy except in sleep 
latency where behavioral therapy revealed a great reduc-
tion in sleep latency. Post-treatment weighted-effect sizes 
included sleep latency (pharmacotherapy Cohen’s d = 0.45, 
behavioral therapy Cohen’s d = 1.05), sleep quality (phar-
macotherapy Cohen’s d = 1.20, behavioral therapy Cohen’s 
d = 1.44), wakefulness after sleep onset (pharmacotherapy 
Cohen’s d = 0.89, behavioral therapy Cohen’s d = 1.03), 
and total sleep time (pharmacotherapy Cohen’s d = 0.84, 
behavioral therapy Cohen’s d = 0.46).27
The American Academy of Sleep Medicine publishes 
practice parameter guidelines for sleep disorders.29 These are 
accompanied by systematic reviews of the evidence support-
ing the recommendations. Two such reviews were conducted 
for insomnia and published by task forces commissioned by 
the American Academy of Sleep Medicine. The first was 
published in 1999 and reviewed 48 clinical trials, and the 
second, published in 2006, reviewed 37 additional treatment 
studies published since the publication of the first review. 
Both concluded that CBTI leads to significant improvements 
in the primary presenting sleep complaint (sleep initiation 
and/or maintenance) with sustained improvement seen for 
6–24 months post-treatment.30
CBTI treatment in the presence of 
comorbidities: recent developments
In the last decade, attention has been given to the applica-
tion of CBTI when experienced in the context of medical 
and psychiatric comorbidities. Insomnia disorder has a high 
comorbidity rate with chronic medical conditions (ranges 
from 20% to 80%).31,32 The challenge in treating insomnia 
that is comorbid with medical conditions is that it is com-
plicated by the direct impact of the comorbid disease and/or 
its treatment on sleep. For example, chronic pain and many 
HIV medications interfere with sleep. The comorbid medical 
disease may also hinder adherence to changes in behaviors 
that are introduced by CBTI. For example, pain and fatigue, 
which are common in many medical diseases, may make 
it difficult, and sometimes unsafe, to get out of bed when 
one is unable to sleep, a key recommendation of stimulus 
Table 1 Description of cognitive behavioral therapy for insomnia 
components
Therapy component Description
Stimulus control Set of instructions aimed at breaking  
conditioned arousal and strengthening the 
bed and bedroom as stimuli for sleep
Sleep restriction Limiting the time allowed in bed to the  
patient’s average reported actual sleep  
time and subsequently slowly increasing the 
time allowed in bed as sleep improves
Cognitive therapy Targets beliefs and thoughts that directly  
interfere with sleep by increasing arousal in 
bed or indirectly by interfering with  
adherence to stimulus control and sleep 
restriction
Relaxation techniques Diaphragmatic breathing, progressive muscle   
relaxation, and visual imagery to reduce  
psychic and somatic anxiety related to sleep
Sleep hygiene education Limiting caffeine intake, avoiding alcohol  
before bed, incorporating daily exercise,  
and keeping the bedroom quiet, dark, and  
at a comfortable temperaturePsychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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control. Nonetheless, CBTI appears to be effective in treating 
insomnia in the context of cancer and chronic pain.33,34 Some 
adaptations for CBTI to the specific comorbid diseases have 
been used. For example, when treating insomnia in cancer 
and HIV patients, CBTI was augmented with counterfatigue 
measures such as scheduled short naps, exercise, and judi-
cious use of caffeine.35–37
Insomnia disorder also has a high comorbidity with 
psychiatric conditions, with estimated prevalence rates 
between 26% and 32%.38,39 Historically, it has been thought 
that sleep disturbances are caused by the psychiatric disorder 
and that when the parent disorder is treated, the sleep dis-
turbance will resolve. There is recent data that suggest that 
the relationship between the psychiatric condition and sleep 
disturbances is more complex.40,41 The data also demonstrate 
that disturbed sleep can be a risk factor for the development 
of psychiatric disorders.42 The challenges in treating insomnia 
that is comorbid with psychiatric conditions is similar to the 
challenges in treating insomnia that is comorbid with medical 
conditions, in that the symptoms of the comorbid psychiatric 
disease and/or its treatment may have a direct impact on sleep 
and adherence to CBTI recommendations. Among the psychi-
atric disorders, depressive disorders and post-traumatic stress 
disorder (PTSD) have received the greatest attention. Uncon-
trolled and controlled pilot studies provide initial evidence 
that CBTI leads to significant improvements in sleep among 
patients with comorbid depressive disorders.43–45 The effects 
of CBTI in depression extend beyond sleep improvement and 
include improvement in depressive symptom severity.41,45,46 
For example, a randomized controlled pilot study found that, 
among patients with comorbid insomnia and major depres-
sive disorder (MDD), CBTI enhanced the antidepressant 
effects of escitalopram when concomitantly administered. 
This study reported remission of MDD in 61.5% of partici-
pants receiving a combination of escitalopram and CBTI, in 
comparison with those who received the medication com-
bined with a control insomnia therapy (33.3%).41 This study 
also found a significantly greater remission of insomnia in 
association with CBTI (50%) than with a control insomnia 
therapy (7.7%). This is a clinically important finding because 
insomnia symptoms are the most common residual symp-
toms of antidepressant treatments that do not target sleep 
improvement, and patients who experience residual insomnia 
are at higher risk for relapse.40,47 This suggests that adding 
treatment for insomnia to standard antidepressant treatment 
in patients with insomnia may need to be considered in the 
clinical management of MDD.47 It has yet to be systematically 
tested whether CBTI is a preventive measure for those with 
insomnia disorder and who are at risk for the development 
of depression.
In those with PTSD, disturbed sleep is one of the most 
frequent symptoms.48,49 As is similarly found in MDD, despite 
remission of PTSD, disturbed sleep remains unresolved in 
48% of patients treated with CBT for PTSD. This is note-
worthy because hypervigilance and nightmares, two hall-
mark symptoms of PTSD, remain unresolved in only 33% 
of patients.50 We found three studies that provide evidence 
that CBTI may be effective for insomnia that is comorbid 
with PTSD. One of the three studies targeted insomnia in 
veterans with comorbid PTSD or other psychiatric or medical 
comorbidities, and the other two included only patients who 
experienced insomnia comorbid with PTSD.51–53
In two studies that focused on PTSD samples, CBTI 
was adapted to the specific needs of PTSD patients who 
commonly experience nightmares. Nightmares not only 
disrupt sleep but also may lead to anticipatory anxiety about 
experiencing nightmares.53,54 To address these issues, CBTI 
was combined with exposure to the nightmare content or 
imagery rehearsal therapy (IRT).54 IRT suggests to patients 
that, over time, nightmares become a learned experience and 
recommends altering (rescripting) the content of dreams by 
activating the imagery system.55,56 Combined CBTI and night-
mare exposure leads to large effect sizes for sleep efficiency 
(Cohen’s d = 1.01), sleep onset latency (Cohen’s d = 0.89), 
and nightmare distress (Cohen’s d = 1.14).54 Randomized 
controlled trials with larger samples are needed to confirm 
these promising preliminary findings.
Another adaptation of CBTI to PTSD was proposed by 
Haynes et al57 but is not yet tested. Standard stimulus control 
guidelines dictate that insomnia sufferers should not get into 
bed until they are sleepy, that they get out of bed if they are 
unable to sleep, and that they return to bed only when they 
are sleepy. Haynes et al suggest that hypervigilance associ-
ated with PTSD may preclude the experience or awareness 
of feeling sleepy and therefore recommend altering stimulus 
control instructions by recommending a set bedtime, even if 
they are not sleepy. They also recommend that when patients 
follow the recommendation to get out of bed when they are 
unable to sleep, they should return to bed after a set amount 
of time (20 minutes), rather than wait until they feel sleepy.57 
Research is needed to test the proposed modifications to CBTI 
and combination of CBTI with nightmare therapies.
CBTI as maintenance therapy
To the best of our knowledge, only one study has examined 
the role of CBT as a maintenance therapy for insomnia.58 Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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This study had a complex design, consisting of essentially 
two separate randomized maintenance therapy trials. In one 
study, participants with persistent insomnia who completed 
six weekly sessions of group CBTI were randomized to 
receive six monthly sessions of individual CBTI as a main-
tenance therapy or 6 months of assessment only. Although 
continued therapy increased the remission rate from 44% 
to 57%, the improvement was similar among those who 
received no maintenance therapy (the observation only 
group), suggesting no added benefit of maintenance therapy 
among those who have previously received CBTI at the 
acute phase of treatment. This may be because CBTI has 
durable effects, as was previously documented, possibly 
because patients utilized skills learned in the acute phase of 
treatment.23–25
The second of the two maintenance studies randomized 
participants with persistent insomnia who completed 6 weeks 
of acute treatment with combined group CBTI and zolpidem 
(10 mg qhs) to receive either six monthly individual CBTI 
sessions plus medication (to be used as needed) or six monthly 
individual CBTI sessions with no additional medication.58 
Maintenance therapy with combined CBTI and zolpidem 
as needed increased remission from 44.4% at the end of the 
acute treatment phase to 59.8% at the end of the maintenance 
phase, as did maintenance therapy with CBTI alone (remission 
increased from 44.4% at the end of the acute phase to 56.9% 
at the end of the 6-month maintenance phase). This suggests 
no advantage for continued medication as needed over CBTI 
among those receiving combination treatment during the 
acute phase. Six-month follow-up data indicate that the best 
long-term trajectory was for those who received combined 
therapy during the acute phase and CBTI alone during the 
maintenance phase. Remission rates in this group continued 
to increase at 6-month follow-up to 68%, whereas the remis-
sion rate at the 6-month follow-up in the group who continued 
medication as needed dropped to 42%.
One interpretation of the results may be that hypnotic 
discontinuation while still receiving CBTI may have created 
an opportunity for patients to successfully handle transient 
worsening of sleep that often accompanies discontinuation. 
This experience might have increased self-efficacy regarding 
the ability to deal with disturbed sleep.
Expanding the mode of delivery: 
recent developments
Despite the existence of an effective and well-tolerated ther-
apy for insomnia, the availability of CBTI to those who need 
it is limited by the small number of qualified behavioral sleep 
medicine specialists and their restricted geographic region.59 
Increasing attention has been given to assessing the efficacy 
of CBTI when delivered in contexts that increase access and 
availability. These include Internet-based CBTI and delivery 
of CBTI by nurses in primary care.
internet delivery
The evolution of the Web has brought about opportunities for 
behavioral medicine treatments to be delivered in an efficient 
manner. There are many advantages to the use of the Internet 
as a vehicle for treatment delivery, such as convenience for 
the patient, a decrease in expense, and accessibility. At the 
same time, it is important to acknowledge limitations related 
to Internet-delivered CBT, such as individualization of treat-
ment to patients’ presenting problems, a lack of provider sup-
port and guidance, and proper patient diagnosis and access 
to the appropriate online treatment.60 Self-help CBTI has 
previously been found effective, as its focused and structured 
nature make it theoretically suitable for adaption to Internet 
delivery.61 The question that arises in delivering CBTI via 
the Internet is whether it is efficacious. This question was 
initially explored in a Swedish population in a randomized 
controlled trial of 109 participants who were randomized 
into a wait-list control group (assessment only) or a 5-week 
online CBTI intervention (sleep restriction, stimulus con-
trol, and cognitive restructuring). Participants receiving the 
CBTI intervention would read the treatment information 
each week, submit a sleep diary, and receive a new time 
in bed prescription calculated by an algorithm. The results 
revealed significant improvement in the treatment group on 
measures such as total sleep time, time awake in the middle 
of the night, and sleep efficiency, although the control group 
also showed improvement. Effect sizes between groups were 
low (Cohen’s d = -0.03).62 Ritterband et al63 have also started 
exploring this area. In a randomized pilot trial, 45 adults were 
randomized to a wait-list control (assessment only) group 
or to receive an Internet CBTI intervention, Sleep Healthy 
Using the Internet (SHUTi). The CBTI intervention included 
sleep restriction, stimulus control, cognitive restructuring, 
sleep hygiene education, and relapse prevention. The par-
ticipants completed a daily sleep diary and based on that 
information received a new time in bed prescription weekly. 
Quizzes were used to test knowledge of the material pre-
sented, and vignettes were used to enhance engagement. The 
study revealed a significant reduction in Insomnia Severity 
Index in the CBTI Internet intervention and no significant 
change for the wait-list group. Improvements were also seen 
in decreased time awake after sleep onset and increased Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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self-reported sleep quality, and the gains were maintained at 
6-month follow-up. The study suggests that an Internet-based 
approach is appealing to participants.64 SHUTi is now being 
tested on a larger scale in a more representative sample that 
includes individuals with comorbid psychological or medical 
conditions.65 These findings are also in line with an Internet 
randomized controlled trial of 118 participants randomized to 
wait-list control (assessment only) or a 5-week CBTI online 
intervention.66 The results included significant improvement 
in insomnia severity, general fatigue, and sleep quality. Due 
to lower adherence to later modules in the active treatment 
group, the question of how to maintain engagement in online 
treatment was raised by the researchers as a future area for 
exploration.
Internet interventions may be a particularly attractive 
mode of delivery to the younger generation. In preparation for 
testing Internet delivery of a sleep intervention to college stu-
dents, Trockel et al67 tested email intervention that consisted 
of eight pdf files, each emailed weekly. The pdf files included 
sleep education, sleep restriction therapy with an emphasis on 
anchoring wake time, stimulus control instructions, relaxation 
and mindfulness training, and restructuring sleep-interfering 
beliefs and cognitions. The pilot study compared a sleep 
health intervention (Refresh), consisting of the same CBTI 
components as SHUTi, and an emotional health (Breathe) 
intervention, based on CBT for depression principles. The 
interventions were delivered in two separate freshmen dorms, 
to avoid cross-contamination of the interventions. The study 
revealed that the sleep health intervention was associated 
with greater improvements in sleep quality and depression 
severity than was the emotional health intervention among 
those with self-reported poor sleep quality (Pittsburgh Sleep 
Quality Index) at baseline.68 Dropout rates among students 
with poor sleep quality were very low, suggesting a high level 
of acceptability. The results, if replicated in a larger sample 
and for Internet delivery, suggest that a self-guided CBTI 
may offer a nonstigmatizing approach for improving sleep 
and reducing depression in college students.
Stepped care model
Another approach to increasing access to CBTI that has 
been receiving increased attention is delivery by nurses in 
primary care settings where patients usually present with 
other comorbid conditions. Espie et al69 first conducted a 
preliminary randomized controlled effectiveness study with 
139 patients with insomnia in Scotland. The study tested 
the effectiveness of six sessions of group CBTI delivered by 
primary care nurses (health visitors) in a primary care setting. 
The results revealed that, among completers, CBTI resulted 
in a substantial reduction of sleep latency and duration of 
wakefulness during the night, which was significantly greater 
than that observed in a self-monitoring control. However, 
effect sizes were smaller than those observed in efficacy 
studies of primary insomnia. These benefits were sustained a 
year later with the additional benefit of a significant increase 
in total sleep time. The intervention included support in 
withdrawal from hypnotics and a schedule of gradual tapering 
negotiated with the patient to maximize adherence, but reduc-
tion rate was not greater than one therapeutic dose per week. 
Of the 74 participants taking hypnotic medication at baseline, 
76% were medication free post-treatment, and most remained 
medication free at 1-year follow-up. In a follow-up larger ran-
domized controlled effectiveness study, this research group 
randomized 201 participants to five sessions of group CBTI 
or treatment as usual.70 The results were similar. Effect size 
for reduction in sleep onset latency was moderate (Cohen’s 
d = 0.58) and for minutes awake after sleep onset the effect 
size was small (Cohen’s d = 0.35).
A more recent study of primary care delivery of CBTI 
focused on a different delivery model.71 Treatment consisted 
of brief behavioral therapy for insomnia. It included two 
in-person sessions delivered by mental health nurses and 
two telephone calls. The first session was 45–60 minutes 
in length and the second session was 30 minutes in length 
and scheduled 2 weeks later along with two telephone calls 
scheduled 1 and 3 weeks after the in-person sessions. The 
content of the sessions consisted of a brief behavioral therapy 
session, which included recommendations regarding reducing 
time in bed, keeping the wake time consistent, not getting 
into bed until sleepy, getting out of bed if not sleeping, and 
discouraging naps. The sample consisted of 79 older adults 
in the United States. The control therapy consisted of reading 
three brochures published by the American Academy of Sleep 
Medicine: Insomnia, Sleep and Aging, and Sleep Hygiene. 
The results also revealed a large effect size (Cohen’s d = 0.96) 
for reduction in latency to sleep onset and a moderate effect 
size for minutes awake after sleep onset (Cohen’s d = 0.59). 
The benefits were maintained at the 6-month follow-up.
Conclusions: place in therapy
Recognition of CBTI as the first-line treatment for chronic 
insomnia (National Institutes of Health consensus, British 
Medical Association) was based largely on evidence of its 
efficacy in primary insomnia.72,73 This manuscript has reviewed 
evidence that CBTI is effective in specific and mixed   comorbid 
samples and when delivered in a primary care setting. We also Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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reviewed emerging data that Internet delivery of CBTI may be 
an effective method of delivery that is acceptable to patients 
and could provide access to care by patients without access 
to behavioral sleep medicine specialists. Future areas of 
research may include Internet-available CBTI for those with 
MDD or other comorbidities, such as those with chronic pain. 
Finally, we reviewed new evidence on the role of CBTI as a 
maintenance therapy for insomnia. When CBTI is delivered in 
combination with a hypnotic medication, long-term outcome 
is enhanced when medications are discontinued during main-
tenance therapy with CBTI. When CBTI is delivered alone, 
maintenance therapy may not be needed. Future research is 
needed to explore in what other situations maintenance CBTI 
is beneficial. These new directions of research inform the 
application of CBTI to “real-world” patients with medical and 
psychiatric comorbidities who may be taking hypnotic medica-
tions and to individuals with limited access to care.
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